Paraoxonase phenotype distribution in a healthy Iranian population

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 2, 2007, Pages 104-107

  Sepahvand, Farideh ^b   Shafiei, Massoumeh ^c   Ghaffari, Seyed Mahmood ^b   Rahimi Moghaddam, Parvaneh ^c   Mahmoudian, Massoud ^a,c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; IRAN; MALE; NORMAL HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SMOKING; STIMULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; FEMALE; GENETICS, POPULATION; HUMANS; IRAN; MALE; MIDDLE AGED; PHENOTYPE; SMOKING; TRIGLYCERIDES;

EID: 34447625599     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00080.x     Document Type: Article

References (24)

1. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 192, for the respective A or B allozymes. Am J Hum Genet 1991 40 : 277 82.
2. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996 7 : 69 76.
3. Aviram M, Ronsenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998 101 : 1581 90.
4. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991 286 : 152 4.
5. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000 275 : 3957 62.
6. Draganov DI, La Du BN. Pharmacogenetics of paraoxonase: A brief review. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 78 88.
7. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999 9 : 745 53.
8. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991 86 : 193 9.
9. Furlong CE, Richter RJ, Seidel SJ, Motulsky A. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988 43 : 230 8.
10. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993 3 : 73 6.
11. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983 35 : 214 27.
12. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase 1. Clin Sci (Lond) 2004 107 : 435 47.
13. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Human Genet 1983 35 : 1126 38.
14. Reiner E, Svedruzic D, Simeon-Rudolf V, Lipovac V, Gavella M, Mrzljak V. Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Chem Biol Interact 1999 120 : 405 11.
15. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 2003 111 : 1403 9.
16. Rojas-Garcia AE, Solis-Heredia MJ, Piña-Guzman B, Vega L, López-Carrillo L, Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005 205 : 282 9.
17. Azizi F, Rahmani M, Raiszadeh F, Solati M, Navab M. Association of lipid, lipoproteins, apolipoproteins and paraoxonase enzyme activity with premature coronary artery disease. Coron Artery Dis 2002 13 : 9 16.
18. Zhou Z, Wu H, Zhou J, Xue S. Activity of serum paraoxonase and its polymorphism in healthy Chinese of Shanghi. Zhonghua Yu Fang Yi Xue Za Zhi 2000 34 : 20 1.
19. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997 236 : 289 93.
20. Sumegova K, Nagyova Z, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase and lipid profile in healthy children. Physiol Res 2006 Jun 22 [Epub ahead of print].
21. Singh S, Verma M, Nain CK, Leelamma CO, Goel RC. Paraoxonase (PON1) polymorphism & its relation with lipids in northwest Indian Punjabis. Indian J Med Res 1999 110 : 133 7.
22. Davies HG, Richter R, Keifer JM, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996 14 : 334 6.
23. Abdollahi M, Jalali N, Sabzevari O, Hoseini R, Ghenea T. A retro-spective study of poisoning in Tehran. J Toxicol Clin Toxicol 1997 35 : 387 93.
24. Ministry of Health Medical Education. Report of the 3rd evaluation of health-for-all strategies up to 2000. Ministry of Health and Medical Education, Tehran 2000.